Sanofi (SNY)
(Delayed Data from NSDQ)
$56.75 USD
-0.71 (-1.24%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $56.73 -0.02 (-0.04%) 6:22 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Price, Consensus and EPS Surprise
SNY 56.75 -0.71(-1.24%)
Will SNY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNY
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine
Other News for SNY
Sanofi in licensing deal for radiopharmaceutical for cancer
Xencor: Vudalimab Development Along With Hidden Gem Candidate
IN BRIEF: Sanofi inks licensing deal for rare cancer treatment
Sanofi, RadioMedix, and Orano Med Announce Licensing Agreement on Next-Generation Radioligand Medicine for Rare Cancers
Fulcrum downgraded after setback for lead program (update)